KR20230056190A - Antibacterial composition comprising Cibotium barometz J. Smith extract as an active ingredient - Google Patents

Abstract

Disclosed is a health functional food composition comprising a Cibotium barometz J. Smith extract as an active ingredient for preventing or alleviating an oral disease, wherein the oral disease includes a periodontal disease caused by porphyromonas gingivalis, dental caries caused by Streptococcus mutans, oral candidiasis caused by Candida albicans, or a root canal disease caused by Enterococcus faecalis.

Description

Antibacterial composition comprising Cibotium barometz J. Smith extract as an active ingredient}

The present invention relates to an antibacterial composition comprising Cibotium barometz J. Smith extract as an active ingredient.

Oral diseases are caused by bacteria, and periodontal disease is the main cause of tooth loss in adults.

Periodontitis, which occurs most frequently among periodontal diseases , is a disease that causes tooth attachment loss by destroying alveolar bone and attachment tissue, and is caused by Porphyromonas gingivalis ; It corresponds to bacteria that have enzymes that degrade proteins constituting gum tissue.

Mutans bacteria ( Streptococcus mutans ; S. mutans ) is attached to the tooth surface in the oral cavity and is the main causative bacterium showing a large number in the dental caries area, and acid causes a demineralization process in tooth enamel to cause dental caries.

Candida albicans ( C albicans ) does not cause disease in healthy people, but it is a disease caused by weakened immunity, general weakness, endocrine disorder, dry mouth, etc., and oral candidiasis occurs in the oral mucosa through opportunistic infection.

Enterococcus faecalis ( E. faecalis ) also occurs in the form of opportunistic infection in connection with inflammation or periodontitis that occurs around the root canal.

In general, antibiotics are used to suppress the causative bacteria that cause these oral diseases. Antibiotics have harmful effects on the human body and can cause side effects such as mycobacteria and formation of resistant bacteria. Recently, the use of natural extracts known to have few side effects has been actively used.

In addition, most consumers currently use existing mouthwashes to manage their oral health, and while mouthwashes have strong antibacterial effects, they contain a large amount of chemicals, which causes problems such as tooth discoloration and damage to the oral mucosa. There have been reports of associations with factors that cause oral cancer, including . When used for a long period of time, chemical substances have physiological risks to the human body, and as controversy over safety arises, many studies and developments on natural extracts that can reduce the side effects of chemicals and safely replace them have been reported.

On the other hand, gucheok ( Cibotium barometz J. Smith) is a dried rhizome of golden hair gucheok belonging to the bracken family, and antioxidant, anti-inflammatory, and growth effects have been reported. It has been reported that the components contained in Gucheok improve liver function, protect the kidneys, relax muscles, edema, diuresis, back and spine pain, and are effective in women's diseases. In addition, studies have been reported that confirmed anti-inflammatory and antioxidant properties, regeneration and recovery of nerve cells, formation and inhibition of osteoclasts, etc.

In the present invention, it relates to an antibacterial composition comprising a Cibotium barometz J. Smith extract prepared and containing it as an active ingredient, Porphyromonas gingivalis bacteria ( porphyromonas gingivalis ), Mutans bacteria ( Streptococcus mutans ), Candida albicans ( Candida albicans ) or Enterococcus faecalis bacteria ( Enterococcus faecalis ) were confirmed to have an excellent antibacterial effect to complete the present invention.

KR 20100008745 A

An object of the present invention is to provide an antibacterial composition comprising Cibotium barometz J. Smith extract as an active ingredient, the extract of the present invention is Porphyromonas gingivalis bacteria ( porphyromonas gingivalis ), Mutans bacteria ( Streptococcus mutans ), Candida albicans or Enterococcus faecalis because it exhibits excellent antibacterial effect, it can be used as an antibacterial composition against these bacteria.

In order to achieve the above object, the present invention provides an antibacterial composition comprising Cibotium barometz J. Smith extract as an active ingredient.

In one embodiment of the present invention, the “gucheok extract” is characterized in that it is extracted with distilled water, ethanol, methanol or a mixed solvent thereof, but is not limited thereto.

In one embodiment of the present invention, "gucheok extract" is characterized in that it is extracted using 60 to 80% ethanol, but is not limited thereto.

In one embodiment of the present invention, the "antibacterial composition" is characterized by inhibiting or killing the growth of bacteria, but is not limited thereto.

In one embodiment of the present invention, "bacteria" is Porphyromonas gingivalis ( porphyromonas gingivalis ) bacteria, mutans bacteria ( Streptococcus mutans ), Candida albicans bacteria ( Candida albicans ) or Enterococcus faecalis bacteria ( Enterococcus faecalis ) It is characterized by, but is not limited thereto.

In one embodiment of the present invention, "gucheok extract" is characterized in that the effective concentration is contained in the range of 20 to 50 mg / ml, but is not limited thereto.

The present invention provides a pharmaceutical composition for the prevention or treatment of oral diseases comprising an extract of Cibotium barometz J. Smith as an active ingredient.

The present invention provides a quasi-drug composition for preventing or improving oral diseases comprising an extract of Cibotium barometz J. Smith as an active ingredient.

The present invention provides a cosmetic composition for preventing or improving oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient.

The present invention gucheok ( Cibotium barometz J. Smith ) Provides a health functional food composition for preventing or improving oral diseases comprising an extract as an active ingredient.

The present invention is an antimicrobial composition comprising an extract of Cibotium barometz J. Smith as an active ingredient. ( Candida albicans ) and Enterococcus faecalis bacteria ( Enterococcus faecalis ) It shows an excellent antibacterial effect.

1 is a diagram showing the killing effect of Porphyromonas gingivalis ( porphyromonas gingivalis ) of the extract of Cibotium barometz J. Smith of the present invention.
Figure 2 is a view showing the killing effect of mutans bacteria ( Streptococcus mutans ) of the gucheok ( Cibotium barometz J. Smith) extract of the present invention.
Figure 3 is a diagram showing the killing effect of Candida albicans of the extract of Cibotium barometz J. Smith of the present invention ( Candida albicans ).
Figure 4 is a diagram showing the killing effect of Enterococcus faecalis of the extract of Cibotium barometz J. Smith of the present invention.
5 is a diagram showing the cytotoxic effect of the Cibotium barometz J. Smith extract of the present invention on human keratinocytes and gingival fibroblasts.
Figure 6 is when the extract of Cibotium barometz J. Smith of the present invention is treated for 6 hours and 24 hours, Porphyromonas gingivalis bacteria ( porphyromonas gingivalis ), mutans bacteria ( Streptococcus mutans ), Candida albicans bacteria ( Candida albicans ) and Enterococcus faecalis ( Enterococcus faecalis ) It is a diagram comparing the killing effect by concentration.

Hereinafter, the present invention will be described in detail as an embodiment of the present invention with reference to the accompanying drawings. However, the following implementation examples are presented as examples of the present invention, and if it is determined that a detailed description of a well-known technology or configuration may unnecessarily obscure the gist of the present invention, the detailed description may be omitted. , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the description of the claims described later and equivalent scopes interpreted therefrom.

In addition, the terminology used in this specification is a term used to appropriately express a preferred embodiment of the present invention, which may vary according to the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the contents throughout this specification. Throughout the specification, when a certain component is said to "include", it means that it may further include other components without excluding other components unless otherwise stated.

In one aspect, it relates to an antibacterial composition comprising Cibotium barometz J. Smith extract as an active ingredient.

The extract according to the present invention may be obtained by extraction and separation from nature using an extraction and separation method known in the art, and the "extract" defined in the present invention refers to an extract ( Cibotium barometz J Smith), and includes, for example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. As an appropriate solvent for extracting the extract from Cibotium barometz J. Smith, any organic solvent acceptable for food science/pharmaceutical/cosmetics may be used, and water or organic solvent may be used, but is not limited thereto. However, for example, purified water, methanol, ethanol, propanol, isopropanol, butanol, alcohol having 1 to 4 carbon atoms including butanol, acetone, ether Various solvents such as ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane can be used alone or in combination. there is. As an extraction method, any one of methods such as hot water extraction, cold brew extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used. In addition, the desired extract may be additionally subjected to a conventional fractionation process or may be purified using a conventional purification method.

There is no limitation on the preparation method of the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention can be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying of the primary extract extracted by the above-described hot water extraction or solvent extraction method. In addition, a fraction further purified from the primary extract using various chromatography methods such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography you can also get Therefore, in the present invention, the extract is a concept that includes all extracts, fractions, and purified products obtained in each step of extraction, fractionation, or purification, and dilutions, concentrates, or dried products thereof.

In one aspect, as a pharmaceutical composition for preventing or treating oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient,

The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus faecalis ) It relates to a pharmaceutical composition for preventing or treating oral diseases caused by root canal diseases.

The "periodontal disease" of the present invention is a disease in which the gingiva, periodontal ligament, and bone tissue supporting the teeth are inflamed, and is often referred to as periodontal disease. It is divided into gingivitis and periodontitis according to the severity of the disease . Gingivitis is a relatively mild form of periodontal disease with a rapid recovery, and the form limited to the gums, that is, soft tissues, is called gingivitis, and the case where such inflammation progresses to the gums and around the gum bones is called periodontitis. There is a V-shaped gap between the gingiva (gum) and the tooth, and oral pathogens attack the area below the gum line in this groove, releasing lipopolysaccharide (LPS), a inflammatory stimulus, resulting in Inflammation is created, such as swelling and bleeding of the gums, which damages the periodontal ligament and adjacent tissues. As periodontitis progresses, it damages the periodontal ligament and even the alveolar bone, eventually leading to tooth loss. Malnutrition such as protein and vitamins, pregnancy, hormonal disorders such as diabetes, smoking, and AIDS can aggravate the disease. In addition, other causes of periodontal disease include dental plaque and calculus. The periodontal disease of the present invention includes all, regardless of the type, as long as the causative bacteria cause periodontal disease, specifically Actinobacillus actinomycetem comitans ( Actinobacillus actinomycetemcomitans ), Porphyromonas gingivalis ( Porphyromonas gingivalis ), other Rella Forsythia ( Tannerella forsythia ), Treponema denticola ( Treponema denticola ) and Fusobacterium nucleatum ( Fusobacterium nucleatum ) One or more species selected from the group consisting of homogeneity may be selected, more specifically, Porphyromonas ginseng It may be Porphyromonas gingivalis .

The Porphyromonas gingivalis is a type of Bacteroide smooth bacteria, and is a Gram-negative and anaerobic bacterium. The Porphyromonas gingivalis is found in the oral cavity where periodontal disease occurs, and is also found in the upper gastrointestinal tract, respiratory tract and colon. In patients with chronic periodontal disease, collagen is degraded by the collagenase enzyme of the bacteria, and the bacteria can invade gingival fibroblasts and survive even under a considerable concentration of antibiotics. In addition, the bacteria can survive for a long time by invading gingival epithelial cells.

"Dental caries" of the present invention is a disease in which tooth enamel is damaged by acid generated when sugar, starch, etc. are decomposed by bacteria living in the mouth, resulting in tooth decay. It not only causes pain, but also causes apical, alveolar bone destruction and tooth loss if it continues to progress. The occurrence of dental caries is closely related to dietary habits and oral microorganisms, and among about 750 species of microorganisms inhabiting the human oral cavity, the representative causative bacteria of dental caries is known as Streptococcus mutans.

The "mutans bacteria ( Streptococcus mutans )" is also called cariogenic bacteria and is a type of streptococcus. Its scientific name is Streptococcus mutans, and it has been pointed out as the main cause of tooth decay along with Lactobacillus. However, as far as is known, mutans causes tooth decay by discoloring teeth black, and in the case of Lactobacillus, which has nothing to do with color change, it causes tooth decay.

“Oral candidiasis” of the present invention refers to a fungal infection caused by various species of Candida sp., in particular, Candida albicans, a yeast-like fungus. Candida species are usually maintained in small amounts in the oral cavity, vagina and intestines of healthy individuals. Infections with Candida fungi usually develop in a depressed immune state and can affect the body as a whole (eg, disseminated or systemic candidiasis) and can be life threatening. The most common candidiasis condition is focal candidiasis. One example is "diaper rash", a form commonly seen in infants. Focal candidiasis can affect the skin, vagina, oral cavity (eg oral candidiasis) and esophagus and in immunocompromised individuals (eg HIV patients).

Oral candidiasis (sometimes referred to as "thrush") is an infection in which fungi (yeasts) of the genus Candida accumulate in the mucous membranes of the oral cavity. It is most frequently caused by Candida albicans, or less commonly by Candida glabrata or Candida tropicalis. When it occurs in the mouth of a baby, candidiasis is commonly called oral thrush, while when it occurs in the mouth or throat of an adult, it may be called candidiasis or moniliasis.

Oral infections caused by Candida spp. can come on suddenly and persist for a long period of time. Candidiasis infections usually appear as thick white or creamy deposits on mucous membranes such as the tongue, inner jaw, gums, tonsils and roof of the mouth. Infected mucous membranes may become inflamed, redness and swelling, and sometimes have a cottage cheese-like appearance. Lesions can be painful and often bleed if rubbed or scraped. Cracks in the corners of the oral cavity may result in a temporary loss of fuzz-like sensation and even taste inside the oral cavity. In more severe cases, the infection can spread down the esophagus, causing dysphagia (dysphagia), sometimes called esophageal candidiasis. Thrush usually does not cause fever unless the infection has spread beyond the esophagus to other parts of the body, such as the lungs (ie systemic candidiasis).

The " Candida albicans" is the most common pathogenic fungus in humans that causes diseases ranging from mucosal infections to systemic infections. Usually, they form colonies on mucosal surfaces without any symptoms as commensal bacteria, but if the host environment is broken or the host's immune disorder is impaired, they can proliferate and invade any part of the body. The excellent adaptability of fungi to transition from commensal bacteria to pathogens is due to a series of virulence factors. In particular, the ability to transform into yeast, pseudohypha and hypha, or form biofilms depending on environmental conditions, is a central characteristic of Candida albicans pathogenicity.

The "root canal disease" of the present invention is an inflammatory lesion in the periodontal tissue around the root canal, which occurs when open pulpitis, pulp necrosis or pulp gangrene, when root canal treatment is insufficient, or when bacteria of low toxicity are present.

The Enterococcus faecalis is a gram-positive cocci belonging to the genus Enterococci and resides mainly in the digestive tract of humans and mammals, and is often found in foods such as vegetables and meat, so it is an indicator of fecal contamination of food. It is also a hygienic factor that affects the shelf life.

The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. Any of the adjuvants known in the art may be used without limitation.

The pharmaceutical composition according to the present invention may be prepared in the form of incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers usable in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin , calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories or sterile injection solutions according to conventional methods, respectively. there is.

When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, and gelatin in addition to active ingredients. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions for oral administration, emulsions, syrups, etc. In addition to commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. can Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for suppositories, witepsol, tween 61, cacao paper, laurin paper, glycerogelatin, and the like may be used.

The pharmaceutical composition according to the present invention can be administered to a subject by various routes. All modes of administration are contemplated, eg oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The pharmaceutical composition may be formulated into various oral or parenteral dosage forms.

Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. chlorose, mannitol, sorbitol, cellulose and/or glycine), lubricants such as silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol. In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid or a disintegrant or effervescent mixture, such as its sodium salt, and/or absorbents, colorants, flavors, and sweeteners. The formulation may be prepared by conventional mixing, granulating or coating methods.

In addition, a typical formulation for parenteral administration is an injection formulation, and water, Ringer's solution, isotonic physiological saline or suspension may be used as a solvent for the injection formulation. Sterile fixed oils of the above injectable preparations may be used as a solvent or suspending medium, and any bland fixed oil may be used for this purpose, including mono- and di-glycerides.

In addition, the formulation for injection may use a fatty acid such as oleic acid.

In one aspect, as a quasi-drug composition for preventing or improving oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient,

The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus faecalis ).

The “quasi-drug composition” of the present invention may include a quasi-drug for oral use. Ingredients included in the quasi-drug composition of the present invention may include ingredients commonly used in oral quasi-drug compositions in addition to the above active ingredients as active ingredients, such as abrasives, wetting agents, binders, foaming agents, sweeteners, preservatives, medicinal ingredients, flavors agents, pigments, solvents, brighteners, solubilizers or pH adjusters.

The "quasi-drug composition for oral use" of the present invention can be prepared in any formulation commonly manufactured in the art, and for example, toothpaste, mouthwash, mouthwash, gum, candy, oral spray, oral ointment, oral It may have formulations such as varnish, mouthwash and gum massage cream, but is not limited thereto.

As an example, when the oral quasi-drug composition of the present invention is a toothpaste formulation, it may contain a wetting agent, an abrasive, a binder, a foaming agent, a flavoring agent, a sweetening agent, a coloring agent, a preservative, a medicinal component, a solvent, a pH adjusting agent, and the like.

The humectant is to make the powder of toothpaste ingredients paste and prevent the toothpaste from hardening in the air, and glycerin, sorbitol, propylene glycol, polyethylene glycol, etc. alone or in combination of two or more, 1 to 60 weight of the total weight of the composition %, specifically, 10 to 50% by weight may be used.

The foaming agent diffuses the toothpaste into the oral cavity to increase the cleaning effect and acts as a surfactant to clean oral contamination. Alternatively, 0.5 to 10% by weight, specifically 0.5 to 5% by weight of the total weight of the composition may be used by mixing two or more kinds.

The binder prevents separation between powder and liquid components in toothpaste, and is a mixture of cellulose derivatives such as sodium carboxymethyl cellulose, methyl cellulose, and hydroxypropyl cellulose, sodium alginate, carrageenan, xanthan gum, etc. alone or in combination of two or more. 0.1 to 5% by weight, specifically 0.3 to 2% by weight of the total weight of the composition may be used.

The abrasive is calcium carbonate (CaCO ₃ ), calcium phosphate dibasic (CaHPO ₄ , CaHPO ₄ 2H ₂ O), silicic anhydride (SiO ₂ 2H ₂ O), aluminum hydroxide (Al(OH) ₃ ), potassium pyrophosphate, magnesium carbonate, etc. alone or in combination of two or more, and 1 to 60% by weight, specifically 10 to 50% by weight of the total weight of the composition can be used

The flavoring agent is to enhance the feeling of use by imparting a refreshing feeling and smell to toothpaste, and peppermint oil, spearmint oil, menthol, etc. alone or in combination of two or more are used in an amount of 0.01 to 60% by weight, specifically 0.01 to 60% by weight of the total weight of the composition. 5% by weight can be used.

The sweetener is to remove the unpleasant taste caused by raw materials for toothpaste and improve the refreshing feeling, and 0.01 to 60% by weight of the total weight of the composition by mixing saccharic acid, aspartame, xylitol, licorice acid, etc. alone or in combination of two or more, specifically 0.01 to 5% by weight can be used.

In one aspect, as a cosmetic composition for preventing or improving oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient,

The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus faecalis ) It relates to a cosmetic composition for preventing or improving oral diseases caused by root canal diseases.

The "cosmetic composition" of the present invention may be prepared by including a cosmetically effective amount of an extract extracted from Cibotium barometz J. Smith and a cosmetically acceptable carrier.

As used herein, the term "cosmetically effective amount" means an amount sufficient to achieve the above-described efficacy of improving neurological diseases of the composition of the present invention.

The appearance of the cosmetic composition contains a cosmetic or dermatologically acceptable medium or base. These are all formulations suitable for topical application, e.g. solutions, gels, solids, anhydrous pasty products, emulsions obtained by dispersing an oily phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and It may be provided in the form of a non-ionic follicular dispersant, or in the form of a cream, toner, lotion, powder, ointment, spray or conceal stick. These compositions can be prepared according to conventional methods in the art. The composition according to the invention can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

The cosmetic composition according to an embodiment of the present invention is not particularly limited in its dosage form, for example, softening lotion, astringent lotion, nutrient lotion, nutrient cream, massage cream, essence, eye cream, eye essence, cleansing It can be formulated into cosmetics such as cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil and body essence.

When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fibers, vegetable fibers, wax, paraffin, starch, tracanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. this can be used

When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additionally chlorofluorohydro propellants such as carbon, propane/butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.

When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, as carrier components, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate , fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives, or ethoxylated glycerol fatty acid esters.

The cosmetic composition of the present invention can be applied to skin, lotion, cream, essence, pack, foundation, color cosmetics, sunscreen, two-way cake, face powder, compact, makeup base, skin cover, eye shadow, lipstick, lip gloss, lip fix, eyebrow pencil , It can be applied to cosmetics such as lotion and detergents such as shampoo and soap.

The cosmetic composition according to an embodiment of the present invention may further include functional additives and components included in general cosmetic compositions in addition to the extract extracted from Cibotium barometz J. Smith. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extracts.

In addition to the above functional additives, the cosmetic composition of the present invention may further contain components included in general cosmetic compositions as needed. Ingredients other than those included include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation accelerators, cooling agents, antiperspirants, purified water and the like.

In one aspect, as a health functional food composition for preventing or improving oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient,

The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus faecalis ) It relates to a health functional food composition for preventing or improving oral disease, which is a root canal disease caused by.

The health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, like conventional food compositions, in addition to containing an extract as an active ingredient.

Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrins, cyclodextrins, and the like, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agents described above, natural flavoring agents (thaumatin), stevia extracts (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can advantageously be used. The food composition of the present invention can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements, etc. there is

In addition, the food composition includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, in addition to extracts that are active ingredients. , alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverages, and vegetable beverages.

The functional food composition of the present invention can be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like. In the present invention, 'health functional food composition' refers to a food manufactured and processed using raw materials or ingredients having useful functionalities for the human body according to the Health Functional Food Act No. 6727, and the structure and function of the human body It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological functions. The health functional food of the present invention may contain ordinary food additives, and the suitability as a food additive is determined according to the general rules of the Food Additive Code and General Test Methods approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to the relevant standards and standards. Examples of the items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations. For example, a health functional food in the form of a tablet is obtained by granulating a mixture obtained by mixing the active ingredient of the present invention with excipients, binders, disintegrants, and other additives in a conventional manner, and then adding a lubricant or the like to compression molding, or as described above. The mixture can be directly compression molded. In addition, the health functional food in the form of a tablet may contain a flavoring agent and the like as needed. Among health functional foods in the form of capsules, hard capsules can be prepared by filling a mixture in which the active ingredient of the present invention is mixed with additives such as excipients in a normal hard capsule. It can be prepared by filling the mixture mixed with gelatin in a capsule base. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. The health functional food in the form of a pill can be prepared by molding a mixture in which the active ingredient of the present invention, excipients, binders, disintegrants, etc. are mixed with a conventionally known method, and if necessary, it can be coated with white sugar or other coating agents, Alternatively, the surface may be coated with a material such as starch or talc. Health functional food in the form of granules can be prepared in granular form by a conventionally known method of mixing a mixture of excipients, binders, disintegrants, etc. of the active ingredients of the present invention, and if necessary, flavoring agents, flavoring agents, etc. can

Hereinafter, the present invention will be described in more detail through examples. However, the above embodiments and experimental examples are presented as examples of the present invention, and detailed descriptions thereof are omitted if it is determined that detailed descriptions of well-known techniques or configurations may unnecessarily obscure the gist of the present invention. It can be done, and the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the scope of the claims described below and equivalents interpreted therefrom.

Example 1. Gucheok ( Cibotium barometz J. Smith) extract preparation

The pulverized gochuk ( Cibotium barometz J. Smith) was mixed with 70% ethanol and shaken at 60° C. for 24 hours. After filtering only the supernatant using filter paper, it was concentrated using a rotary vacuum evaporator (N-1300E.VS EYELA Co., Tokyo, Japan). The concentrated extract was used after being lyophilized with a freeze dryer (FD, Ilshin Lab, Yangju, Korea).

Example 2. Cultivation of strains

Streptococcus mutans ( Deposit: KCTC 3065) and Enterococcus faecalis ( Deposit: KCTC 2011) were tested for Candida albicans in brain heart infusion broth (BHI; Sigma-Aldrich, St. Louis, MO, USA). Candida albicans , deposited: KCTC 7965) was cultured in an environment maintained at 37˚C for 24 hours after subculturing the strain in yeast mold broth (YM, Difco, USA), and Porphyromonas gingivalis ( porphyromonas gingivalis , Deposit: KCTC 5352) was anaerobically cultured in tryptic soy broth (BD Difco, USA).

Example 3. Gucheok ( Cibotium barometz J. Smith) Confirmation of cytotoxicity of the extract

3-1. Human keratinocytes (hereafter, HaCaT)

HaCaT cells, which are human keratinocytes, are normal cells related to the oral cavity and were distributed from the American Type Culture Collection (Rockville, MD, USA) and used in this experiment. Culture conditions were Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Hyclone, South Logan, UT, USA) and 1% antibiotics (100 U/ml penicillin G, 100 mg/ml streptomycin, Hyclone). Incubated at 37°C, 5% CO2.

The quantification of the effect on the cell growth rate according to the application of the extract of Guchi extract was measured by applying the WST-1 (water soluble tetrazoliumsalt-1) analysis. HGF cells were cultured in a 96-well plate at concentrations of 0.01 mg/ml, 0.05 mg/ml, 0.1 mg/ml, 0.3 mg/ml, 0.5 mg/ml, 1 mg/ml, 3 mg/ml, 5 mg/ml, and 10 mg/ml. The treated cells were cultured for 6 hours and 24 hours and then treated with WST-1 solution. After reacting in a 37°C, 5% CO2 incubator for 2 hours, the growth rate was measured at a wavelength of 450 nm with an ELISA reader (Multiskan FC, Thermo isher Scientific, Waltham, MA, USA), and each analysis was independently performed three times. did

As a result of confirming the effect on HaCaT cells according to the application time, 6h did not affect cell viability up to 3mg/ml, indicating that it was safe without cytotoxicity, but it was confirmed that low cell viability appeared at 5mg/ml. It was confirmed that cell viability was affected from 3 mg/ml. It was confirmed that the concentration of the extract of Gucheok increased in the cells related to the oral cavity and the survival rate of the cells decreased with time.

3-2. Human gingival fibroblast (HGF)

Human gingival fibroblasts, HGF-1 cells, are normal cells related to the oral cavity and were purchased from ATCC (CRL-2014; Rockville, MD, USA) and supplemented with 10% fetal bovine serum (Hyclone, South Logan, UT, USA) and 1% antibiotics. (100 U/ml penicillin G, 100 μg/ml streptomycin, Hyclone) was added to Dulbecco's modified Eagle's medium (DMEM) medium at 37°C and 5% CO2.

The quantification of the effect on the cell growth rate according to the application of the extract of Guchi extract was measured by applying WST-1 (water soluble tetrazoliumsalt-1) analysis. HGF cells were cultured in a 96-well plate at concentrations of 0.01 mg/ml, 0.05 mg/ml, 0.1 mg/ml, 0.3 mg/ml, 0.5 mg/ml, 1 mg/ml, 3 mg/ml, 5 mg/ml, and 10 mg/ml. The treated cells were cultured for 6 hours and 24 hours and then treated with WST-1 solution. After reacting in a 37°C, 5% CO2 incubator for 2 hours, the growth rate was measured at a wavelength of 450 nm with an ELISA reader (Multiskan FC, Thermo isher Scientific, Waltham, MA, USA), and each analysis was independently performed three times. did

As a result of confirming the effect on HGF-1 cells according to the application time, 6h did not affect cell viability up to 5mg/ml, indicating that it was safe without cytotoxicity, but it was confirmed that low cell viability appeared at 10mg/ml. 24h was confirmed to affect cell viability from 5mg/ml. It was confirmed that the concentration of the extract of Gucheok increased in the cells related to the oral cavity and the survival rate of the cells decreased with time.

Example 4. Gucheok ( Cibotium barometz J. Smith) Confirmation of antibacterial activity of the extract

Viable counts of Cibotium barometz J. Smith extract against Porphyromonas gingivalis , Streptococcus mutans , Candida albicans and Enterococcus faecalis To confirm, colony-forming units (CFUs) were measured. After diluting the extract to the concentration corresponding to each strain in tryptic soy broth, BHI broth, and YM broth, 1 × 106 P. gingivalis, 1 × 105 S. mutans, E. faecalis, and 1 × 104 C. albicans were mixed. In order to check the change over time, after anaerobic culture at 37 °C, tryptic soy blood agar medium was smeared and cultured. After aerobic culture, BHI agar medium and YM agar medium were smeared and incubated for 6 hours and 24 hours, then colony forming units (colony -forming units; CFUs) were identified.

As a result, Porphyromonas gingivalis bacteria ( porphyromonas gingivalis ) It can be seen that 99.99% killing at a concentration of 10mg / ml when applied. When applied to mutans bacteria ( Streptococcus mutans ), it can be confirmed that 99.99% death at a concentration of 5mg/ml in 6 hours and 99.99% death at a concentration of 15mg/ml after 24 hours can be confirmed. When applied to Candida albicans, 99.99% killing at a concentration of 5mg/ml can be confirmed in 6 hours, and 99.99% killing at a concentration of 10mg/ml can be confirmed after 24 hours. When applied to Enterococcus faecalis , it was confirmed that 99.99% death was confirmed at a concentration of 10 mg/ml in 6 hours, and 99.99% death was confirmed at a concentration of 15 mg/ml after 24 hours (Table 1). .

P. gingivalis
inhibitor (%) 0.01 mg/ml 0.05 mg/ml 0.1 mg/ml 0.3 mg/ml 0.5 mg/ml 1 mg/ml 3 mg/ml 5 mg/ml 10 mg/ml 15 mg/ml 20 mg/ml 25 mg/ml 30 mg/ml 35 mg/ml 40 mg/ml 6h 12.12 22.04 26.72 43.53 84.13 98.89 99.60 99.87 99.998 99.99996 99.999992 99.9999973 99.9999974 99.9999981 100.00 24h 0.67 6.26 17.14 40.63 63.85 93.77 93.87 97.70 99.996 99.999998 99.99999999990 99.999999999967 100.00 S. mutans
inhibitor (%) 0.01 mg/ml 0.05 mg/ml 0.1 mg/ml 0.3 mg/ml 0.5 mg/ml 1 mg/ml 3 mg/ml 5 mg/ml 10 mg/ml 15 mg/ml 20 mg/ml 25 mg/ml 30 mg/ml 35 mg/ml 40 mg/ml 45 mg/ml 6h 74.29 77.14 96.93 99.11 99.76 99.79 99.98 99.99 99.9997 99.9998 99.99996 99.999991 99.999994 99.999995 99.999997 100.00 24h 34.85 40.42 42.90 58.67 67.21 92.99 98.63 99.04 99.83 99.999986 99.9999997 99.99999991 100.00 E. faecalis
inhibitor (%) 0.01 mg/ml 0.05 mg/ml 0.1 mg/ml 0.3 mg/ml 0.5 mg/ml 1 mg/ml 3 mg/ml 5 mg/ml 10 mg/ml 15 mg/ml 20 mg/ml 25 mg/ml 30 mg/ml 35 mg/ml 40 mg/ml 6h 6.74 7.45 26.60 80.14 91.10 98.90 99.57 99.81 100.00 99.99993 99.99998 99.999994 99.999994 99.9999996 100.00 24h 12.47 88.51 88.90 88.97 89.03 98.86 98.96 99.12 99.96 99.9999992 99.9999999996 100.00 100.00 C. albicans
inhibitor (%) 0.01 mg/ml 0.05 mg/ml 0.1 mg/ml 0.3 mg/ml 0.5 mg/ml 1 mg/ml 3 mg/ml 5 mg/ml 10 mg/ml 15 mg/ml 20 mg/ml 25 mg/ml 6h 88.10 92.81 95.36 98.40 98.53 99.55 99.963 99.9935 99.9989 99.99983 99.999978 100.00 24h 6.75 20.82 31.92 34.21 61.67 97.59 97.67 99.92 99.9995 99.9999998 99.999999995 100.00

In addition, as the concentration increased, it was confirmed that a more pronounced antibacterial effect was shown (FIG. 6), and as the contact time increased, it was confirmed through the log index that a clear killing effect was shown at a lower concentration (FIG. 6).

As a result, it was confirmed that the extract of Gucheok ( Cibotium barometz J. Smith ) exhibits an antibacterial effect in a short time at a low concentration and can be used as a composition for preventing or treating diseases caused by ~ bacteria.

Claims (10)

Gucheok ( Cibotium barometz J. Smith) Antibacterial composition comprising an extract as an active ingredient. According to claim 1,
The gucheok extract is distilled water, ethanol, methanol or a mixture of these solvents to be extracted, the antimicrobial composition. According to claim 2,
The gucheok extract is extracted using 60 to 80% ethanol, antimicrobial composition. According to any one of claims 1 to 3,
The composition is to inhibit or kill the growth of bacteria, antimicrobial composition. According to claim 4,
The bacterium is Porphyromonas gingivalis ( porphyromonas gingivalis ) bacteria, mutans bacteria ( Streptococcus mutans ), Candida albicans bacteria ( Candida albicans ) or Enterococcus faecalis bacteria ( Enterococcus faecalis ), which is an antibacterial composition. According to claim 1,
The effective concentration of the gucheok extract will be contained in the range of 20 to 50 mg / ml, antimicrobial composition. A pharmaceutical composition for preventing or treating oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient,
The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus faecalis ), which is a root canal disease caused by oral disease prevention or treatment pharmaceutical composition. A quasi-drug composition for preventing or improving oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient,
The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus faecalis ) Quasi-drug composition for preventing or improving oral disease, which is a root canal disease caused by. A cosmetic composition for preventing or improving oral diseases comprising Cibotium barometz J. Smith extract as an active ingredient,
The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus A cosmetic composition for preventing or improving oral disease, which is a root canal disease caused by faecalis ). A health functional food composition for preventing or improving oral diseases containing Cibotium barometz J. Smith extract as an active ingredient,
The oral disease is Lefiromonas gingivalis ( porphyromonas gingivalis ) periodontal disease, mutans ( Streptococcus mutans ) due to dental caries, Candida albicans bacteria ( Candida albicans ) Oral candidiasis or Enterococcus faecalis ( Enterococcus faecalis ), which is a root canal disease caused by oral disease prevention or improvement of health functional food composition.

Images